As previously reported, a potential use to assess the risk of disease progression has been proposed, because an increase in plasma levels of sCD163 was observed on hospital admission in COVID-19 patients, especially in those who developed ARDS, as well as its correlation with typical inflammatory markers of COVID-19 pneumonia [43,44]. This evidence concerns the gene CD163 and acute respiratory distress syndrome.